Melda Onal

Federal Grant PI

Assistant Professor

Last publication 2025 Last refreshed 2026-05-23

faculty

Physiology & Cell Biology, College of Medicine

19 h-index 38 pubs 3,170 cited

Biography and Research Information

OverviewAI-generated summary

Melda Onal's research program investigates the biological mechanisms underlying bone health and development, with a particular focus on the role of cellular processes like autophagy and the regulation of osteoblast and osteoclast activity. Her work utilizes genetically engineered mouse models to study the in vivo consequences of specific genetic alterations on bone mass, density, and strength.

Onal has received federal funding from the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases for her project "CRISPR inhibition as an alternate for Cre-loxP," totaling $162,184. This grant supports her investigation into novel methods for generating genetically engineered animal models, exploring the specificity and efficacy of CRISPR interference compared to traditional Cre-loxP systems.

Her publications address topics such as the identity of mesenchymal cell types in bone, the impact of chaperone-mediated autophagy loss on bone mass, and the effects of altering autophagy regulators like Tfeb in osteoblast lineage cells. She also examines the role of mitochondrial oxidative stress and decreased autophagy in age-related bone changes. Onal collaborates with researchers at the University of Arkansas for Medical Sciences, including Jinhu Xiong, Charles A. O’Brien, Maria Almeida, and A. Gordon James, with whom she has co-authored multiple publications. Her scholarship metrics include an h-index of 19, 38 total publications, and over 3,100 citations.

Metrics

  • h-index: 19
  • Publications: 38
  • Citations: 3,170

Selected Publications

  • TFEB-mediated autophagy stimulation as an anabolic strategy for bone: insights from TFEB activation in the osteoblast lineage (2025)
    1 citation DOI OpenAlex
  • The Aging Landscape by <scp>scRNAseq</scp> of Mesenchymal Lineage Cells in Mouse Bone (2025)
    2 citations DOI OpenAlex
  • Elevation of master autophagy regulator Tfeb in osteoblast lineage cells increases bone mass and strength (2025)
    5 citations DOI OpenAlex
  • Mitochondrial oxidative stress or decreased autophagy in osteoblast lineage cells is not sufficient to mimic the deleterious effects of aging on bone mechanoresponsiveness (2025)
    4 citations DOI OpenAlex
  • A new <i>Col1a1</i> conditional knock-in mouse model to study osteogenesis imperfecta (2024)
    1 citation DOI OpenAlex
  • CRISPR activation of <i>Tfeb</i> , a master regulator of autophagy and lysosomal biogenesis, in osteoblast lineage cells increases bone mass and strength (2024)
    1 citation DOI OpenAlex
  • Refining the identity of mesenchymal cell types associated with murine periosteal and endosteal bone (2024)
    23 citations DOI OpenAlex
  • Loss of chaperone‐mediated autophagy does not alter age‐related bone loss in male mice (2024)
    3 citations DOI OpenAlex
  • A framework for defining mesenchymal cell types associated with murine periosteal and endosteal bone (2023)
    1 citation DOI OpenAlex
  • CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system (2023)
    6 citations DOI OpenAlex
  • Novel methods for the generation of genetically engineered animal models (2022)
    7 citations DOI OpenAlex
  • Loss of chaperone-mediated autophagy is associated with low vertebral cancellous bone mass (2022)
    12 citations DOI OpenAlex
  • Deletion of a putative promoter-proximal Tnfsf11 regulatory region in mice does not alter bone mass or Tnfsf11 expression in vivo (2021)
    7 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $162,184 total

NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases Contact PI Jan 2020 - Dec 2021

CRISPR inhibition as an alternate for Cre-loxP

National Institute of Arthritis and Musculoskeletal and Skin Diseases $162,184 R21

Grants & Funding

  • CRISPR inhibition as an alternate for Cre-loxP NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases Principal Investigator
  • Center for Musculoskeletal Disease Research (CMDR) NIH/Nat. Inst. of General Medical Sciences Principal Investigator
  • DEAP Awards - P. Drew - UAMS VCRI - FY26 Role of Oligodendrocyte-Lineage Cells in FASD UAMS Division of Research and Innovation Principal Investigator
  • Center for Musculoskeletal Disease Research (CMDR) NIH/Nat. Inst. of General Medical Sciences Principal Investigator

Collaboration Network

42 Collaborators 4 Institutions 2 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics